AzTrials
AzTrials

Status; SplenectomyNCT02079064

Effects of Desflurane Versus Propofol on Hemostasis During Splenectomy

A study testing Desflurane and Propofol in people with Status; Splenectomy, run by Theodor Bilharz Research Institute at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this prospective randomized study is to evaluate the perioperative effects of inhalational anesthesia (desflurane) and intravenous anesthesia (propofol) on hemostasis in patients undergoing splenectomy with liver cirrhosis guided by the new technology (ROTEM) and the traditional laboratory hemostatic… Read more about this study

Who is it for?
Ages 25 to 55 years
Conditions the study is for
Status; Splenectomy
What is being tested?
Desflurane and Propofol
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteEgypt
Study dates
Jan 2014to Jul 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patient ASA physical status II and III.
  • Age between 22-55 years.
  • Child A suffering from pancytopenia.
  • Type of surgery: splenectomy

Who cannot join

  • Patients using oral anticoagulants
  • Patients using antithrombotic drugs
  • Patients using non steroidal anti-inflammatory drugs
  • Patients using oral contraceptives
  • Age less than 25 or more than 55 years
  • Obese patients (body mass index >35 kg m-2)
  • Pregnancy and lactation

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Theodor Bilharz Research Institute

    Giza, 12411

Other trials in Egypt

About this study

Official title: Perioperative Effect of Desflurane Versus Total Intravenous Anesthesia With Propofol on Hemostasis Guided by Thromboelastometry in Splenectomy With Liver Cirrhosis.

The aim of this prospective randomized study is to evaluate the perioperative effects of inhalational anesthesia (desflurane) and intravenous anesthesia (propofol) on hemostasis in patients undergoing splenectomy with liver cirrhosis guided by the new technology (ROTEM) and the traditional laboratory hemostatic markers.

Read the detailed description

After obtaining approval from the Institutional Research Ethics Committee and informed written consent, thirty adult patients aged 25- 55 years of either sex, American Society of Anesthesiologists (ASA) class II- III (Child A) suffering from cytopenia scheduled for elective splenectomy will be recruited. Pancytopenia is defined as anemia (hemoglobin < 13.5 g/dL-male; <12 g/dL-female); leucopenia (total leukocyte count < 4,000/mm3) and thrombocytopenia (platelet count < 150,000/mm3). Child B and C, Hb < 10 g/dL platelet count < 50,000/mm3, White Blood Cells (WBCs) < 2,000/mm3, prothrombin time [PT] > 16 s and INR > 1.7, extremes of age, obese patients (body mass index >35 kg m-2), and those using oral anticoagulants, other antithrombotic drugs, or oral contraceptives, will be excluded from the study.

All patients will be premedicated with 0.05 mg kg-1 i.v midazolam half an hour before operation. In the operating room, continuous pulse oximetry, electrocardiogram, non-invasive arterial blood pressure, PECO2, end-tidal anesthetic agent, neuromuscular monitoring, core temperature (Infinity Kappa, Dräger, Lübeck, Germany) and hourly urine output will be monitored throughout the operation. Depth of anesthesia will be monitored by using Bispectral index (BIS). All IV fluids will be warmed, and a warm air blanket (Bair Hugger) will be applied to every patient.

Thirty eligible patients will be allocated randomly to one of two equal groups (15 patients each) according to a computer generated randomization list: group D; maintenance of anesthesia with inhaled desflurane at 1 minimum alveolar concentration (MAC); group P, maintenance of anesthesia with target-controlled infusion (TCI) propofol with a target plasma concentration of propofol between 2 and 5 µg ml-1. The concentration of volatile anesthetics or the rate of infusion of injected anesthetics will be titrated to maintain the BIS numerical value between 40-50.

Anesthesia will be induced in both groups using i.v. fentanyl 1.5- 2 µg kg-1 and propofol 2- 2.5 mg kg-1. Atracurium 0.5 mg kg-1 will be administered for neuromuscular block and continued according to the response to train-of-four peripheral nerve stimulation. After intubation, patients will be mechanically ventilated with 30% oxygen in air throughout surgery using a low flow system (1L min-1) to adjust an end-tidal carbon dioxide (PECO2) between 30- 35 mmHg. Acetated Ringer's solution will be given as a preload and maintenance at a rate of 5-7 ml kg-1 h-1. Patients' systolic arterial pressures will be maintained at 100 mmHg or 70% of the preoperative value, whichever is higher. Hypotension will be treated with i.v. crystalloid fluid loading or intravenous boluses of ephedrine as appropriate. No colloid transfusion will be allowed. Transfusions of red blood cells will be used to maintain hemoglobin levels equal to or above 8 g dl-1. Platelets or fresh frozen plasma will be infused only when indicated by ROTEM. At the end of surgery, neuromuscular blockade will be antagonized with 0.05 mg kg-1 neostigmine and 0.02 mg kg-1 atropine. Postoperative analgesia was provided by intravenous infusion of 1 gm acetaminophen and IV meperidine 1 mg kg-1 every 12 hours. Patients are given an anti-emetic ondansetron 4 mg postoperatively.

Blood Sampling:

Five blood samples will be collected; before operation, after ligation of splenic artery, immediate post-operative, 24 hours and three days after the operation. Each time, five ml of venous blood will be collected and assessment of the following parameters will be performed:

Complete blood picture:

  1. Hemoglobin Concentration (by electronic cell counter).
  2. Hematocrit (by electronic cell counter).
  3. Platelet count (by electronic cell counter).
  4. Red blood cells (by electronic cell counter).
  5. White blood cells (by electronic cell counter).

Screening hemostatic tests:

  1. Prothrombin Time (PT) (by conventional method).
  2. International Normalized Ratio (INR) (by conventional method).
  3. Partial Thromboplastin Time (PTT) (by conventional method).

Specific hemostatic tests:

  1. Soluble platelet selectin (sP-selectin) [enzyme-linked immunosorbent assay (ELISA)].
  2. Fibrinogen level (coagulation method).
  3. D-dimer level (ELIZA).

At each sample time (0.3 ml blood) will be taken for measuring the following ROTEM variables:

  • The time until initial fibrin formation (clotting time CT).
  • The kinetics of fibrin formation and clot development (clot formation time (CFT) and α- angle).
  • The ultimate strength and stability of the fibrin clot (maximum clot firmness MCF).
  • Clot lysis (fibrinolysis). The previous parameters provide information about platelet activation, fibrin formation and clot retraction (all stages of the developing and resolving clot). Blood samples are activated extrinsically (by tissue factor) and intrinsically (by contact activator) via commercially available tests. Furthermore, fibrinogen levels will be assessed by measuring clot strength (MCF) in the presence of platelet inhibition (e.g., fib-TEM). This modified MCF represents the fibrin clot that developed in the absence of any platelets, i.e., the functional fibrinogen [6].

Routine laboratory tests:

  1. Serum creatinine.
  2. Alanine aminotransferase (ALT),aspartate aminotransferase (AST), albumin, bilirubin.

Routine investigations will be performed pre-, post-operative and on the third day.

Follow up of each patient will be done at out-patients clinic after one month to have thorough clinical examination, liver and kidney function tests, Child's Turcotte Pugh (CTP) score assessment, laboratory hematological tests and ROTEM assessment. This is important to assess post-operative complications, efficacy of splenectomy in improving cytopenia, and the influence of splenectomy on the natural course of disease.

Statistical Analysis:

No previous study was conducted to assess the effects of anesthetic agents on hemostasis during splenectomy with liver cirrhosis guided by ROTEM. Thus the calculation of the sample size is difficult and also the reagents required for ROTEM are expensive so we designed this thesis to be a pilot study. A sample size was chosen to be 15 patients in each group. Comparison between the two groups will be performed using Mann-Whitney test, while comparison within each group will be performed using Wilcoxon sign rank test. Comparison between repeated measures in both groups was performed using ANOVA. The data are considered significant if p values are ≤ 0.05. Statistical analysis will be performed with the aid of the Statistical Package for the Social Sciences (SPSS) computer program, version 12 windows (IBM, USA).

.

Being tested
Desflurane, Propofol
Keywords
Splenectomy, Desflurane, Propofol, TCI, ROTEM

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DesfluraneDrug

    Also called Suprane

    Inhalational anesthetic

  • PropofolDrug

    Also called Diprivan

    Intravenous anesthetic that can be given by continuous infusion

Study groups in NCT02079064
Study groupRoleWhat they receive
DesfluraneExperimentalDesflurane at 1 MAC and
Receives: Drug: Desflurane
propofolExperimentalpropofol TCI (target controlled infusion) infusion of to keep a target plasma concentration between 2 and 5 µg ml-1
Receives: Drug: Propofol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. maximum clot firmness (MCF)

    Ultimate strength and stability of the fibrin clot measured by ROTEM.

    Measured: Up to 1 month

Secondary outcomes (9)
  1. clotting time CT

    The time until initial fibrin formation measured by ROTEM

    Measured: Up to 1 month

  2. clot formation time; CFT

    The kinetics of fibrin formation and clot development measured by ROTEM

    Measured: Up to 1 month

  3. D dimer

    Indication of coagulation and fibrinolysis

    Measured: Up to 1 month

  4. Platelet count

    Ability of clot formation

    Measured: Up to 1 month

  5. Prothrombin Time

    measures of the extrinsic pathway of coagulation

    Measured: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation

  6. International Normalized Ratio (INR)

    measures of the extrinsic pathway of coagulation

    Measured: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation

  7. sP-selectin

    Acts as a receptor that supports binding of leukocytes to activated platelets and endothelium.

    Measured: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation

  8. Fibrinogen Level

    A soluble plasma glycoprotein, that is converted by thrombin into fibrin during blood clot formation

    Measured: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation

  9. D-Dimer

    A fibrin degradation product (or FDP) present in the blood after a blood clot is degraded by fibrinolysis

    Measured: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Mar 2014 (estimated)
  2. Study startJan 2014
  3. Primary completionJun 2017
  4. Study completionJul 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02079064
Sponsor's protocol ID
Anesthesia 98T
Status last verified
Oct 2016
First submitted
27 Feb 2014
Last updated
11 Oct 2017
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol. 2006 Dec 28;12(48):7725-36. doi: 10.3748/wjg.v12.i48.7725.

    PubMed 17203512
  • Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci. 2003 Sep;326(3):111-6. doi: 10.1097/00000441-200309000-00001.

    PubMed 14501224

Questions about this trial

What is this clinical trial studying?

A study testing Desflurane and Propofol in people with Status; Splenectomy, run by Theodor Bilharz Research Institute at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

maximum clot firmness (MCF) (time frame: Up to 1 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02079064, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Oct 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in